GlassScriptPhysician profile
David A Raskin
NPI 1457354003
$348.07
in general payments reported to CMS, 2019-2025
13 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.65 · 2022: $18.00 · 2023: $65.11 · 2024: $94.27 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258 · Education: $24.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $258.06 |
| Education | $24.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $63.99 | 2024-2025 | Acthar |
| Travere Therapeutics, INC. | $32.73 | 2024-2025 | Filspari |
| Horizon Therapeutics Plc | $32.69 | 2022-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $31.16 | 2019-2025 | Voyxact |
| Ani Pharmaceuticals, INC. | $27.37 | 2023 | Purified Cortrophin Gel |
| Amgen INC. | $26.81 | 2025 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $25.68 | 2024 | Lokelma |
| Amicus Therapeutics, INC. | $23.05 | 2023 | Galafold |
| Organogenesis INC. | $19.72 | 2025 | Affinity |
| Alnylam Pharmaceuticals INC. | $18.08 | 2024 | Oxlumo |
| Daiichi Sankyo INC. | $16.15 | 2025 | Injectafer |
| Emd Serono, INC. | $15.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Raskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.